Cell-Free Circulating Epimarks in Cancer Monitoring

References

• Allis CD , CaparrosM-L , JenuweinT , ReinbergD , LachlanM. Epigenetics, 2nd Edition. Cold Spring Harbor Laboratory Press. (2015).
   Google Scholar
• Kanwal R , GuptaS. Epigenetic modifications in cancer. Clin. Genet.81(4), 303–311 (2012).
   PubMed Web of Science ®Google Scholar
• Mandel P , MetaisP. Les acides nucléiques du plasma sanguin chez l’homme. C. R. Seances Soc. Biol. Fil.142(3–4), 241–243 (1948).
   PubMedGoogle Scholar
• Barnett EV . Detection of nuclear antigens (DNA) in normal and pathologic human fluids by quantitative complement fixation. Arthritis Rheum.11(3), 407–417 (1968).
   PubMedGoogle Scholar
• Davis GL , DavisJS. Detection of circulating DNA by counterimmunoelectrophoresis (CIE). Arthritis Rheum.16(1), 52–58 (1973).
   PubMedGoogle Scholar
• Chan AKC , ChiuRWK , LoYMD. Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Ann. Clin. Biochem.40(2), 122–130 (2003).
   PubMedGoogle Scholar
• Fleischhacker M , SchmidtB. Circulating nucleic acids (CNAs) and cancer – a survey. Biochim. Biophys. Acta BBA Rev. Cancer1775(1), 181–232 (2007).
   PubMed Web of Science ®Google Scholar
• Moss J , MagenheimJ , NeimanDet al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat. Commun.9(1), 5068 (2018).
   PubMed Web of Science ®Google Scholar
• Anker P , StrounM , MauricePA. Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system. Cancer Res.35(9), 2375–2382 (1975).
   PubMed Web of Science ®Google Scholar
• Rogers JC , BoldtD , KornfeldS , SkinnerA , ValeriCR. Excretion of deoxyribonucleic acid by lymphocytes stimulated with phytohemagglutinin or antigen. Proc. Natl Acad. Sci. USA69(7), 1685–1689 (1972).
   PubMed Web of Science ®Google Scholar
• Han X , WangJ , SunY. Circulating tumor DNA as biomarkers for cancer detection. Genomics Proteomics Bioinformatics15(2), 59–72 (2017).
   PubMed Web of Science ®Google Scholar
• Lo YM , CorbettaN , ChamberlainPFet al. Presence of fetal DNA in maternal plasma and serum. Lancet350(9076), 485–487 (1997).
   PubMed Web of Science ®Google Scholar
• Rodrigues Filho EM , SimonD , IkutaNet al. Elevated cell-free plasma DNA level as an independent predictor of mortality in patients with severe traumatic brain injury. J. Neurotrauma31(19), 1639–1646 (2014).
   PubMed Web of Science ®Google Scholar
• Borissoff JI , JoosenIA , VersteylenMOet al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler. Thromb. Vasc. Biol.33(8), 2032–2040 (2013).
   PubMed Web of Science ®Google Scholar
• Hummel EM , HessasE , MüllerSet al. Cell-free DNA release under psychosocial and physical stress conditions. Transl. Psychiatry8(1), 236 (2018).
   PubMed Web of Science ®Google Scholar
• Lanman RB , MortimerSA , ZillOAet al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS ONE10(10), e0140712 (2015).
   PubMed Web of Science ®Google Scholar
• Elshimali YI , KhaddourH , SarkissyanM , WuY , VadgamaJV. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int. J. Mol. Sci.14(9), 18925–18958 (2013).
   PubMed Web of Science ®Google Scholar
• Abolhassani M , TillotsonJ , ChiaoJ. Characterization of the release of DNA by a human leukemia-cell line hl-60. Int. J. Oncol.4(2), 417–421 (1994).
   PubMed Web of Science ®Google Scholar
• Stroun M , LyauteyJ , LederreyC , Olson-SandA , AnkerP. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin. Chim. Acta Int. J. Clin. Chem.313(1–2), 139–142 (2001).
   PubMed Web of Science ®Google Scholar
• Bronkhorst AJ , WentzelJF , AucampJ , van DykE , du PlessisL , PretoriusPJ. Characterization of the cell-free DNA released by cultured cancer cells. Biochim. Biophys. Acta BBA Mol. Cell Res.1863(1), 157–165 (2016).
   PubMed Web of Science ®Google Scholar
• Jahr S , HentzeH , EnglischSet al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res.61(4), 1659–1665 (2001).
   PubMed Web of Science ®Google Scholar
• Holdenrieder S . Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR. Clin. Chem.51(8), 1544–1546 (2005).
   PubMed Web of Science ®Google Scholar
• Snyder MW , KircherM , HillAJ , DazaRM , ShendureJ. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell164(1–2), 57–68 (2016).
   PubMed Web of Science ®Google Scholar
• Tamkovich SN . Circulating nucleic acids in blood of healthy male and female donors. Clin. Chem.51(7), 1317–1319 (2005).
   PubMed Web of Science ®Google Scholar
• Kaiser J . Keeping tabs on tumor DNA. Science327(5969), 1074–1074 (2010).
   PubMedGoogle Scholar
• Wan JCM , MassieC , Garcia-CorbachoJet al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer17, 223 (2017).
   PubMed Web of Science ®Google Scholar
• Diehl F , LiM , DressmanDet al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl Acad. Sci. USA102(45), 16368–16373 (2005).
   PubMed Web of Science ®Google Scholar
• Bettegowda C , SausenM , LearyRJet al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med.6(224), 224ra24–224ra24 (2014).
   PubMed Web of Science ®Google Scholar
• Kamat AA , BischoffFZ , DangDet al. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol. Ther.5(10), 1369–1374 (2006).
   PubMed Web of Science ®Google Scholar
• Jiang P , LoYMD. The long and short of circulating cell-free DNA and the ins and outs of molecular diagnostics. Trends Genet.32(6), 360–371 (2016).
   PubMed Web of Science ®Google Scholar
• Underhill HR , KitzmanJO , HellwigSet al. Fragment length of circulating tumor DNA. PLoS Genet.12(7), e1006162 (2016).
   PubMed Web of Science ®Google Scholar
• Cristiano S , LealA , PhallenJet al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature570(7761), 385–389 (2019).
   PubMed Web of Science ®Google Scholar
• Kwapisz D . The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?Ann. Transl. Med.5(3), 46 (2017).
   PubMed Web of Science ®Google Scholar
• Choudhury AD , WernerL , FranciniEet al. Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight(2018). https://insight.jci.org/articles/view/122109
   PubMed Web of Science ®Google Scholar
• Li H , JingC , WuJet al. Circulating tumor DNA detection: a potential tool for colorectal cancer management (Review). Oncol. Lett. (2018). https://doi.org/10.3892/ol.2018.9794
   Web of Science ®Google Scholar
• Lin L-H , ChangK-W , KaoS-Y , ChengH-W , LiuC-J. Increased plasma circulating cell-free DNA could be a potential marker for oral cancer. Int. J. Mol. Sci.19(11), 3303 (2018).
   PubMed Web of Science ®Google Scholar
• Montagut C , VidalJ , VisaL. KRAS mutations in ctDNA: a promising new biomarker in advanced pancreatic cancer. Ann. Oncol.29(12), 2280–2282 (2018).
   PubMed Web of Science ®Google Scholar
• Panagopoulou M , KaraglaniM , BalgkouranidouIet al. Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers. Oncogene (2019). http://www.nature.com/articles/s41388-018-0660-y
   PubMed Web of Science ®Google Scholar
• Corcoran RB , ChabnerBA. Application of cell-free DNA analysis to cancer treatment. N. Engl. J. Med.379(18), 1754–1765 (2018).
   PubMed Web of Science ®Google Scholar
• Jones PA , BaylinSB. The epigenomics of cancer. Cell128(4), 683–692 (2007).
   PubMed Web of Science ®Google Scholar
• Gai W , SunK. Epigenetic biomarkers in cell-free DNA and applications in liquid biopsy. Genes10(1), 32 (2019).
   PubMed Web of Science ®Google Scholar
• Lehmann-Werman R , NeimanD , ZemmourHet al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc. Natl Acad. Sci. USA113(13), E1826–E1834 (2016).
   PubMed Web of Science ®Google Scholar
• Shen SY , SinghaniaR , FehringerGet al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature563(7732), 579–583 (2018).
   PubMed Web of Science ®Google Scholar
• Sun K , JiangP , ChanKCAet al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc. Natl Acad. Sci. USA112(40), E5503–E5512 (2015).
   PubMed Web of Science ®Google Scholar
• Moss J , MagenheimJ , NeimanDet al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat. Commun.9(1), 5068 (2018).
   PubMed Web of Science ®Google Scholar
• Tóth K , GalambO , SpisákSet al. The influence of methylated septin 9 gene on RNA and protein level in colorectal cancer. Pathol. Oncol. Res.17(3), 503–509 (2011).
   PubMed Web of Science ®Google Scholar
• Payne SR . From discovery to the clinic: the novel DNA methylation biomarker m SEPT9 for the detection of colorectal cancer in blood. Epigenomics2(4), 575–585 (2010).
   PubMed Web of Science ®Google Scholar
• Wang Y , ChenP-M , LiuR-B. Advance in plasma SEPT9 gene methylation assay for colorectal cancer early detection. World J. Gastrointest. Oncol.10(1), 15–22 (2018).
   PubMed Web of Science ®Google Scholar
• Cai L , HoodS , KallamEet al. Epi proColon®: use of a non-invasive SEPT9 gene methylation blood test for colorectal cancer screening: a national laboratory experience. J. Clin. Epigenetics(2018). http://clinical-epigenetics. imedpub.com/epi-procolon-use-of-a-noninvasive-sept9-gene-methylation-blood-test-for-colorectal-cancer-screening-a-national-laboratory-experien.php?aid=22115
   Google Scholar
• Potter NT , HurbanP , WhiteMNet al. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clin. Chem.60(9), 1183–1191 (2014).
   PubMed Web of Science ®Google Scholar
• Fu B , YanP , ZhangSet al. Cell-free circulating methylated SEPT9 for noninvasive diagnosis and monitoring of colorectal cancer. Dis. Markers2018, 1–11 (2018).
   Web of Science ®Google Scholar
• Song L , GuoS , WangJet al. The blood mSEPT9 is capable of assessing the surgical therapeutic effect and the prognosis of colorectal cancer. Biomark. Med.12(9), 961–973 (2018).
   PubMed Web of Science ®Google Scholar
• Xu R , WeiW , KrawczykMet al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat. Mater.16, 1155 (2017).
   PubMed Web of Science ®Google Scholar
• Widschwendter M , ZikanM , WahlBet al. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Med.9(1), (2017). https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-017-0500-7
   Google Scholar
• Rohanizadegan M . Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker. Cancer Genet.228–229; 159–168 (2018).
   Web of Science ®Google Scholar
• Mundbjerg K , ChopraS , AlemozaffarMet al. Identifying aggressive prostate cancer foci using a DNA methylation classifier. Genome Biol. (2017). http://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-1129-3
   Web of Science ®Google Scholar
• Kornberg RD . Chromatin structure: a repeating unit of histones and DNA. Science184(4139), 868–871 (1974).
   PubMed Web of Science ®Google Scholar
• Bednar J , HorowitzRA , GrigoryevSAet al. Nucleosomes, linker DNA, and linker histone form a unique structural motif that directs the higher-order folding and compaction of chromatin. Proc. Natl Acad. Sci. USA95(24), 14173–14178 (1998).
   PubMed Web of Science ®Google Scholar
• Luger K , MäderAW , RichmondRK , SargentDF , RichmondTJ. Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature389(6648), 251–260 (1997).
   PubMed Web of Science ®Google Scholar
• Simpson RT . Structure of the chromatosome, a chromatin particle containing 160 base pairs of DNA and all the histones. Biochemistry17(25), 5524–5531 (1978).
   PubMed Web of Science ®Google Scholar
• Bannister AJ , KouzaridesT. Regulation of chromatin by histone modifications. Cell Res.21(3), 381–395 (2011).
   PubMed Web of Science ®Google Scholar
• Zentner GE , HenikoffS. Regulation of nucleosome dynamics by histone modifications. Nat. Struct. Amp Mol. Biol.20, 259 (2013).
   PubMed Web of Science ®Google Scholar
• Sims RJ , BelotserkovskayaR , ReinbergD. Elongation by RNA polymerase II: the short and long of it. Genes Dev.18(20), 2437–2468 (2004).
   PubMed Web of Science ®Google Scholar
• Tessarz P , KouzaridesT. Histone core modifications regulating nucleosome structure and dynamics. Nat. Rev. Mol. Cell Biol.15(11), 703–708 (2014).
   PubMed Web of Science ®Google Scholar
• Strahl BD , AllisCD. The language of covalent histone modifications. Nature403(6765), 41–45 (2000).
   PubMed Web of Science ®Google Scholar
• Zhang Z , WippoCJ , WalM , WardE , KorberP , PughBF. A packing mechanism for nucleosome organization reconstituted across a eukaryotic genome. Science332(6032), 977–980 (2011).
   PubMed Web of Science ®Google Scholar
• Huertas D , SendraR , MuñozP. Chromatin dynamics coupled to DNA repair. Epigenetics4(1), 31–42 (2009).
   PubMed Web of Science ®Google Scholar
• Jezek M , GreenEM. Histone modifications and the maintenance of telomere integrity. Cells8(2), 199 (2019).
   PubMed Web of Science ®Google Scholar
• Portela A , EstellerM. Epigenetic modifications and human disease. Nat. Biotechnol.28(10), 1057–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Fraga MF , BallestarE , Villar-GareaAet al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet.37(4), 391 (2005).
   PubMed Web of Science ®Google Scholar
• Fahrner JA , EguchiS , HermanJG , BaylinSB. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res.62(24), 7213–7218 (2002).
   PubMed Web of Science ®Google Scholar
• Kondo Y , ShenL , SuzukiSet al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol. Res.37(11), 974–983 (2007).
   PubMed Web of Science ®Google Scholar
• Wozniak RJ , KlimeckiWT , LauSS , FeinsteinY , FutscherBW. 5-Aza-2′-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene26(1), 77–90 (2007).
   PubMed Web of Science ®Google Scholar
• Paschall AV , YangD , LuCet al. H3K9 trimethylation silences Fas expression to confer colon carcinoma immune escape and 5-fluorouracil chemoresistance. J. Immunol.195(4), 1868–1882 (2015).
   PubMed Web of Science ®Google Scholar
• Millan-Zambrano G , Santos-RosaH , PudduF , RobsonSC , JacksonSP , KouzaridesT. Phosphorylation of histone H4T80 triggers DNA damage checkpoint recovery. Mol. Cell.72(4), 625–635.e4 (2018).
   PubMed Web of Science ®Google Scholar
• Seibert M , KrügerM , WatsonNAet al. CDK1-mediated phosphorylation at H2B serine 6 is required for mitotic chromosome segregation. J. Cell Biol.218(4), 1164–1181 (2019).
   PubMed Web of Science ®Google Scholar
• Liu Y , LongY-H , WangS-Qet al. JMJD6 regulates histone H2A. X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity. Oncogene38(7), 980–997 (2019).
   PubMed Web of Science ®Google Scholar
• Mahajan K , MallaP , LawrenceHRet al. ACK1/TNK2 regulates histone H4 Tyr88-phosphorylation and AR gene expression in castration-resistant prostate cancer. Cancer Cell.31(6), 790–803.e8 (2017).
   PubMed Web of Science ®Google Scholar
• Yang W , XiaY , HawkeDet al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell150(4), 685–696 (2012).
   PubMed Web of Science ®Google Scholar
• Yoon S , EomGH. HDAC and HDAC inhibitor: from cancer to cardiovascular diseases. Chonnam Med. J.52(1), 1–11 (2016).
   PubMedGoogle Scholar
• Sun W , LvS , LiH , CuiW , WangL. Enhancing the anticancer efficacy of immunotherapy through combination with histone modification inhibitors. Genes(2018). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315613/
   Web of Science ®Google Scholar
• Karachaliou N , Mayo-de-las-CasasC , Molina-VilaMA , RosellR. Real-time liquid biopsies become a reality in cancer treatment. Ann. Transl. Med.(2015). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356857/
   Google Scholar
• Enari M , SakahiraH , YokoyamaH , OkawaK , IwamatsuA , NagataS. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature391(6662), 43–50 (1998).
   PubMed Web of Science ®Google Scholar
• Holdenrieder S , DharumanY , StandopJet al. Novel serum nucleosomics biomarkers for the detection of colorectal cancer. Anticancer Res.34(5), 2357–2362 (2014).
   PubMed Web of Science ®Google Scholar
• Xu J , ZhangX , PelayoRet al. Extracellular histones are major mediators of death in sepsis. Nat. Med.15(11), 1318–1321 (2009).
   PubMed Web of Science ®Google Scholar
• Allam R , KumarSVR , DarisipudiMN , AndersH-J. Extracellular histones in tissue injury and inflammation. J. Mol. Med. Berl. Ger.92(5), 465–472 (2014).
   PubMed Web of Science ®Google Scholar
• Chen R , KangR , FanX-G , TangD. Release and activity of histone in diseases. Cell Death Dis.5(8), e1370 (2014).
   PubMedGoogle Scholar
• Kuroi K , TanakaC , ToiM. Plasma nucleosome levels in node-negative breast cancer patients. Breast Cancer6(4), 361–364 (1999).
   PubMedGoogle Scholar
• Holdenrieder S , StieberP , BodenmüllerHet al. Circulating nucleosomes in serum. Ann. NY Acad. Sci.945(1), 93–102 (2006).
   Google Scholar
• Kutcher ME , XuJ , VilardiRF , HoC , EsmonCT , CohenMJ. Extracellular histone release in response to traumatic injury: implications for a compensatory role of activated protein C. J. Trauma Acute Care Surg.73(6), 1389–1394 (2012).
   PubMed Web of Science ®Google Scholar
• Rahier J-F , DruezA , FaugerasLet al. Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer. Clin. Epigenetics9(53), (2017).
   PubMedGoogle Scholar
• Rasmussen L , ChristensenIJ , HerzogM , MicallefJ , NielsenHJ. For the Danish Collaborative Group on EA. Circulating cell-free nucleosomes as biomarkers for early detection of colorectal cancer. Circulating cell-free nucleosomes as biomarkers for early detection of colorectal cancer. Oncotarget9(12), 10247–10258 (2017).
   PubMedGoogle Scholar
• Holdenrieder S , StieberP , von PawelJet al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.10(18 Pt 1), 5981–5987 (2004).
   PubMed Web of Science ®Google Scholar
• Fahmueller YN , NagelD , HoffmannR-Tet al. Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing selective internal radiation therapy. BMC Cancer12, 5 (2012).
   PubMed Web of Science ®Google Scholar
• Stoetzer OJ , FerschingDMI , SalatCet al. Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin. Cancer Lett.336(1), 140–148 (2013).
   PubMed Web of Science ®Google Scholar
• Messaoudi K , ClavreulA , LagarceF. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. Drug Discov. Today20(7), 899–905 (2015).
   PubMed Web of Science ®Google Scholar
• Maleszewska M , KaminskaB. Is glioblastoma an epigenetic malignancy?Cancers5(4), 1120–1139 (2013).
   PubMedGoogle Scholar
• Pacaud R , CherayM , NadaradjaneA , ValletteFM , CartronP-F. Histone H3 phosphorylation in GBM: a new rational to guide the use of kinase inhibitors in anti-GBM therapy. Theranostics5(1), 12–22 (2015).
   PubMed Web of Science ®Google Scholar
• ENCODE Project Consortium , BirneyE , StamatoyannopoulosJAet al.Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature447(7146), 799–816 (2007).
   PubMed Web of Science ®Google Scholar
• Ransohoff JD , WeiY , KhavariPA. The functions and unique features of long intergenic non-coding RNA. Nat. Rev. Mol. Cell Biol.19(3), 143–157 (2018).
   PubMed Web of Science ®Google Scholar
• Bach D-H , LeeSK , SoodAK. Circular RNAs in cancer. Mol. Ther. Nucleic Acids.16, 118–129 (2019).
   PubMedGoogle Scholar
• Esteller M . Non-coding RNAs in human disease. Nat. Rev. Genet.12(12), 861–874 (2011).
   PubMed Web of Science ®Google Scholar
• Enache LS , EnacheEL , RamièreCet al. Circulating RNA molecules as biomarkers in liver disease. Int. J. Mol. Sci.15(10), 17644–17666 (2014).
   PubMed Web of Science ®Google Scholar
• Turchinovich A , BurwinkelB. Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma. RNA Biol.9(8), 1066–1075 (2012).
   PubMed Web of Science ®Google Scholar
• Umu SU , LangsethH , Bucher-JohannessenCet al. A comprehensive profile of circulating RNAs in human serum. RNA Biol.15(2), 242–250 (2018).
   PubMed Web of Science ®Google Scholar
• Heneghan HM , MillerN , KerinMJ. Circulating microRNAs: promising breast cancer Biomarkers. Breast Cancer Res. BCR.13(1), 402; author reply 403 (2011).
   PubMed Web of Science ®Google Scholar
• Butova R , Vychytilova-FaltejskovaP , SouckovaA , SevcikovaS , HajekR. Long non-coding RNAs in multiple myeloma. Non-Coding RNA.5(1), (2019).
   PubMed Web of Science ®Google Scholar
• Jeck WR , SharplessNE. Detecting and characterizing circular RNAs. Nat. Biotechnol.32(5), 453–461 (2014).
   PubMed Web of Science ®Google Scholar
• Hu X , BaoJ , WangZet al. The plasma lncRNA acting as fingerprint in non-small-cell lung cancer. Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med.37(3), 3497–3504 (2016).
   PubMedGoogle Scholar
• Masuda T , HayashiN , KurodaY , ItoS , EguchiH , MimoriK. MicroRNAs as biomarkers in colorectal cancer. Cancers9(9), 124 (2017).
   PubMed Web of Science ®Google Scholar
• Wang X , FangL. Advances in circular RNAs and their roles in breast cancer. J. Exp. Clin. Cancer Res. CR37(1), 206 (2018).
   PubMed Web of Science ®Google Scholar
• Peng H , WangJ , LiJet al. A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer. Life Sci.151, 235–242 (2016).
   PubMed Web of Science ®Google Scholar
• El-Tawdi AHF , MatboliM , ShehataHHet al. Evaluation of circulatory RNA-based biomarker panel in hepatocellular carcinoma. Mol. Diagn. Ther.20(3), 265–277 (2016).
   PubMed Web of Science ®Google Scholar
• Huang S-K , LuoQ , PengHet al. A panel of serum noncoding RNAs for the diagnosis and monitoring of response to therapy in patients with breast cancer. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res.24, 2476–2488 (2018).
   Google Scholar
• Nadaradjane A , BriandJ , Bougras-CartronGet al. miR-370-3p is a therapeutic tool in anti-glioblastoma therapy but is not an intratumoral or cell-free circulating biomarker. Mol. Ther. Nucleic Acids13, 642–650 (2018).
   PubMedGoogle Scholar
• Baylin SB , OhmJE. Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?Nat. Rev. Cancer.6(2), 107–116 (2006).
   PubMed Web of Science ®Google Scholar
• Füllgrabe J , KavanaghE , JosephB. Histone onco-modifications. Oncogene30(31), 3391–3403 (2011).
   PubMed Web of Science ®Google Scholar
• Fiala C , DiamandisEP. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Med.(2018). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167864/
   PubMed Web of Science ®Google Scholar
• Pardini B , SaboAA , BiroloG , CalinGA. Noncoding RNAs in extracellular fluids as cancer biomarkers: The new frontier of liquid biopsies. Cancers11(8), 1170 (2019).
   PubMed Web of Science ®Google Scholar
• McAnena P , BrownJAL , KerinMJ. Circulating nucleosomes and nucleosome modifications as biomarkers in cancer. Cancers9(1), 5 (2017).
   PubMed Web of Science ®Google Scholar
• Dumitrescu RG (Ed.). Early epigenetic markers for precision medicine. In: Cancer Epigenetics for Precision Medicine.VermaM ( Ed.). Springer, NY, USA, 3–17 (2018). https://doi.org/10.1007/978-1-4939-8751-1_1
   Google Scholar
• Yong E . Cancer biomarkers: written in blood. Nature511(7511), 524–526 (2014).
   PubMedGoogle Scholar